Cargando…

UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants

Constitutional pathogenic variants in TP53 are associated with Li-Fraumeni syndrome or the more recently described heritable TP53-related cancer syndrome and are associated with increased lifetime risks of a wide spectrum of cancers. Due to the broad tumour spectrum, surveillance for this patient gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanson, Helen, Brady, Angela F, Crawford, Gillian, Eeles, Rosalind A, Gibson, Sarah, Jorgensen, Mette, Izatt, Louise, Sohaib, Aslam, Tischkowitz, Marc, Evans, D Gareth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848057/
https://www.ncbi.nlm.nih.gov/pubmed/32571901
http://dx.doi.org/10.1136/jmedgenet-2020-106876
_version_ 1783645047318642688
author Hanson, Helen
Brady, Angela F
Crawford, Gillian
Eeles, Rosalind A
Gibson, Sarah
Jorgensen, Mette
Izatt, Louise
Sohaib, Aslam
Tischkowitz, Marc
Evans, D Gareth
author_facet Hanson, Helen
Brady, Angela F
Crawford, Gillian
Eeles, Rosalind A
Gibson, Sarah
Jorgensen, Mette
Izatt, Louise
Sohaib, Aslam
Tischkowitz, Marc
Evans, D Gareth
author_sort Hanson, Helen
collection PubMed
description Constitutional pathogenic variants in TP53 are associated with Li-Fraumeni syndrome or the more recently described heritable TP53-related cancer syndrome and are associated with increased lifetime risks of a wide spectrum of cancers. Due to the broad tumour spectrum, surveillance for this patient group has been limited. To date, the only recommendation in the UK has been for annual breast MRI in women; however, more recently, a more intensive surveillance protocol including whole-body MRI (WB-MRI) has been recommended by International Expert Groups. To address the gap in surveillance for this patient group in the UK, the UK Cancer Genetics Group facilitated a 1-day consensus meeting to discuss a protocol for the UK. Using a preworkshop survey followed by structured discussion on the day, we achieved consensus for a UK surveillance protocol for TP53 carriers to be adopted by UK Clinical Genetics services. The key recommendations are for annual WB-MRI and dedicated brain MRI from birth, annual breast MRI from 20 years in women and three-four monthly abdominal ultrasound in children along with review in a dedicated clinic.
format Online
Article
Text
id pubmed-7848057
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-78480572021-02-08 UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants Hanson, Helen Brady, Angela F Crawford, Gillian Eeles, Rosalind A Gibson, Sarah Jorgensen, Mette Izatt, Louise Sohaib, Aslam Tischkowitz, Marc Evans, D Gareth J Med Genet Position Statement Constitutional pathogenic variants in TP53 are associated with Li-Fraumeni syndrome or the more recently described heritable TP53-related cancer syndrome and are associated with increased lifetime risks of a wide spectrum of cancers. Due to the broad tumour spectrum, surveillance for this patient group has been limited. To date, the only recommendation in the UK has been for annual breast MRI in women; however, more recently, a more intensive surveillance protocol including whole-body MRI (WB-MRI) has been recommended by International Expert Groups. To address the gap in surveillance for this patient group in the UK, the UK Cancer Genetics Group facilitated a 1-day consensus meeting to discuss a protocol for the UK. Using a preworkshop survey followed by structured discussion on the day, we achieved consensus for a UK surveillance protocol for TP53 carriers to be adopted by UK Clinical Genetics services. The key recommendations are for annual WB-MRI and dedicated brain MRI from birth, annual breast MRI from 20 years in women and three-four monthly abdominal ultrasound in children along with review in a dedicated clinic. BMJ Publishing Group 2021-02 2020-06-22 /pmc/articles/PMC7848057/ /pubmed/32571901 http://dx.doi.org/10.1136/jmedgenet-2020-106876 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Position Statement
Hanson, Helen
Brady, Angela F
Crawford, Gillian
Eeles, Rosalind A
Gibson, Sarah
Jorgensen, Mette
Izatt, Louise
Sohaib, Aslam
Tischkowitz, Marc
Evans, D Gareth
UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants
title UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants
title_full UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants
title_fullStr UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants
title_full_unstemmed UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants
title_short UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants
title_sort ukcgg consensus group guidelines for the management of patients with constitutional tp53 pathogenic variants
topic Position Statement
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848057/
https://www.ncbi.nlm.nih.gov/pubmed/32571901
http://dx.doi.org/10.1136/jmedgenet-2020-106876
work_keys_str_mv AT hansonhelen ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants
AT bradyangelaf ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants
AT crawfordgillian ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants
AT eelesrosalinda ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants
AT gibsonsarah ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants
AT jorgensenmette ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants
AT izattlouise ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants
AT sohaibaslam ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants
AT tischkowitzmarc ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants
AT evansdgareth ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants
AT ukcggconsensusgroupguidelinesforthemanagementofpatientswithconstitutionaltp53pathogenicvariants